ImmunityBio Shares Surge on Clinical and Commercial Milestones
Published on 01/19/2026 at 08:12 | Redaktion boerse-global.de
A convergence of robust clinical data, explosive revenue growth, and a key international regulatory approval has propelled ImmunityBio’s stock to dramatic gains this week. The biopharmaceutical company’s recent announcements have ignited investor enthusiasm, raising the central question of whether this rally is built on a foundation sustainable for the long term.
The momentum began earlier in the week with the release of preliminary full-year 2025 figures. ImmunityBio reported preliminary net product revenue for its therapy Anktiva of approximately $113 million. This staggering figure represents growth of roughly 700% year-over-year and exceeded analyst expectations, providing the first clear evidence of the drug’s commercial traction—a critical metric for emerging biotech Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
